Quarterly report [Sections 13 or 15(d)]

Fair Value Measurements - Financial Assets and Liabilities Carried at FV on Recurring Basis (Details)

v3.25.3
Fair Value Measurements - Financial Assets and Liabilities Carried at FV on Recurring Basis (Details) - USD ($)
$ in Thousands
Sep. 30, 2025
Dec. 31, 2024
Assets:    
Exarafenib milestone asset $ 3,500 $ 3,214
Castle Creek warrants 595  
Liabilities:    
Exarafenib milestone contingent consideration 3,500 3,214
Fair Value, Recurring    
Assets:    
Cash equivalents 35,007 92,671
Investment in equity securities 1,521 3,529
Exarafenib milestone asset 3,500 3,214
Castle Creek warrants 595  
Total financial assets 40,623 99,414
Liabilities:    
Exarafenib milestone contingent consideration 3,500 3,214
Total financial liabilities 3,500 3,214
Fair Value, Recurring | Money market funds    
Assets:    
Cash equivalents 8,805 72,304
Fair Value, Recurring | U.S. treasury bills    
Assets:    
Cash equivalents 26,202 20,367
Fair Value, Recurring | Quoted Prices in Active Markets for Identical Assets (Level 1)    
Assets:    
Cash equivalents 35,007 92,671
Investment in equity securities 1,521 3,529
Total financial assets 36,528 96,200
Fair Value, Recurring | Quoted Prices in Active Markets for Identical Assets (Level 1) | Money market funds    
Assets:    
Cash equivalents 8,805 72,304
Fair Value, Recurring | Quoted Prices in Active Markets for Identical Assets (Level 1) | U.S. treasury bills    
Assets:    
Cash equivalents 26,202 20,367
Fair Value, Recurring | Significant Unobservable Inputs (Level 3)    
Assets:    
Exarafenib milestone asset 3,500 3,214
Castle Creek warrants 595  
Total financial assets 4,095 3,214
Liabilities:    
Exarafenib milestone contingent consideration 3,500 3,214
Total financial liabilities $ 3,500 $ 3,214